HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a $36 price target.
June 07, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Pliant Therapeutics and maintained a $36 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $36 price target by a reputable analyst suggests positive sentiment and confidence in Pliant Therapeutics' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100